# Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

> **NCT03916419** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 26 (actual)

## Conditions studied

- Stage IIB Non-Small Cell Lung Cancer
- Stage IIIA Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IIIC Non-Small Cell Lung Cancer

## Interventions

- **DEVICE:** ViewRay MR-Linear Accelerator
- **RADIATION:** Radiation therapy
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin AUC
- **BIOLOGICAL:** Durvalumab

## Key facts

- **NCT ID:** NCT03916419
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-20
- **Primary completion:** 2025-09-28
- **Final completion:** 2025-09-28
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03916419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03916419, "Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT03916419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*